| Symbol | BLTE |
|---|---|
| Name | BELITE BIO, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5820 OBERLIN DRIVE,SUITE 101, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 246-6240 |
| Fax | — |
| — | |
| Website | https://www.belitebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. Additional info from NASDAQ: |
MATA NATHAN L. 🔴 sold 1.0K shares of BELITE BIO, INC (BLTE) at $164.07 Transaction Date: Apr 27, 2026 | Filing ID: 187224
Read moreMATA NATHAN L. 🔴 sold 1.0K shares of BELITE BIO, INC (BLTE) at $162.53 Transaction Date: Apr 24, 2026 | Filing ID: 182316
Read moreMATA NATHAN L. 🔴 sold 1.0K shares of BELITE BIO, INC (BLTE) at $167.34 Transaction Date: Apr 21, 2026 | Filing ID: 170443
Read moreMATA NATHAN L. 🔴 sold 1.0K shares of BELITE BIO, INC (BLTE) at $168.35 Transaction Date: Apr 20, 2026 | Filing ID: 167281
Read moreBelite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
Read moreMATA NATHAN L. 🔴 sold 1.0K shares of BELITE BIO, INC (BLTE) at $163.32 Transaction Date: Apr 17, 2026 | Filing ID: 164014
Read moreMATA NATHAN L. 🔴 sold 1.0K shares of BELITE BIO, INC (BLTE) at $164.12 Transaction Date: Apr 16, 2026 | Filing ID: 164012
Read moreMATA NATHAN L. 🔴 sold 1.0K shares of BELITE BIO, INC (BLTE) at $171.19 Transaction Date: Apr 15, 2026 | Filing ID: 159036
Read more📋 Nathan L. Mata (Officer) plans to sell 17K shares of Belite Bio, Inc. (at $171.93 each, total $2.9M) Filed: Apr 15, 2026 | ID: 000357
Read moreLin Yu-Hsin 🔴 sold 9.2K shares of BELITE BIO, INC (BLTE) at $183.00 ($1.7M) Transaction Date: Apr 09, 2026 | Filing ID: 152885
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06388083 | A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subject… | Phase2 | STGD1 | Active_Not_Recruiting | 2024-07-31 | 2028-02-01 | ClinicalTrials.gov |
| NCT05949593 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety … | Phase3 | Geographic Atrophy | Active_Not_Recruiting | 2023-07-27 | 2027-08-31 | ClinicalTrials.gov |
| NCT05667688 | Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Ag… | Phase1 | Healthy Volunteer | Completed | 2022-11-28 | 2023-01-18 | ClinicalTrials.gov |
| NCT05244304 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety … | Phase3 | Stargardt Disease 1 | Completed | 2022-03-28 | 2025-09-12 | ClinicalTrials.gov |
| NCT05266014 | This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Saf… | Phase1 | Stargardt Disease | Completed | 2021-03-12 | 2023-08-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tinlarebant (LBS-008) | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05667688 |
| tinlarebant | DRUG | Phase PHASE1 | Stargardt Disease | COMPLETED | NCT05266014 |
| Tinlarebant | DRUG | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| Placebo | DRUG | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| BPN-14967 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04005807 |
| Placebos | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |
| LBS-008 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |